Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jan 14, 2020Co-Diagnostics’ CoPrimer platform, licensed by LGC, Biosearch, successfully used by Bayer to develop assays for multiplex PCR
Salt Lake City, Utah – January 9, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...
-
Jan 9, 2020
Salt Lake City, Utah – January 9, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...
-
Jan 7, 2020
Salt Lake City, Utah – January 7, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...
-
Jan 2, 2020CoSara tests for tuberculosis, malaria, hepatitis B, hepatitis C, and human papillomavirus recently granted regulatory approval by CDSCO to formally launch at India Diagnostic Expo
Salt Lake City, Utah – January 2, 2020 – Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of...
-
Dec 11, 2019
Salt Lake City, Utah – December 11, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), was recently featured in an article on genomeweb.com titled “Co-Diagnostics Continues Global Expansion With...